ResMed (RMD) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $2.43, $0.11 better than the analyst estimate of $2.32. Revenue for the quarter came in at $1.28 billion versus the consensus estimate of $1.27 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is Treasury selloff a major issue for stock market bulls?
- Benchmark Reiterates Buy Rating on Ooma (OOMA)
- Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
